Edition:
United Kingdom

Bristol-Myers Presents Updated Data From Mid-Stage Trial Of Empliciti Plus Pomalidomide And Dexamethasone In Multiple Myeloma


Friday, 14 Jun 2019 

June 14 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB PRESENTS UPDATED EFFICACY DATA FROM PHASE 2 TRIAL OF EMPLICITI (ELOTUZUMAB) PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM).BRISTOL-MYERS SQUIBB CO - EMPLICITI-BASED COMBINATION SHOWED IMPROVEMENTS ACROSS EFFICACY ENDPOINTS.BRISTOL-MYERS SQUIBB CO - EMPLICITI-BASED COMBINATION SHOWED IMPROVEMENTS ACROSS EFFICACY ENDPOINTS.BRISTOL-MYERS - IN DESCRIPTIVE ANALYSIS, ADDITION OF EMPLICITI TO POMALIDOMIDE AND DEXAMETHASONE REDUCED RISK OF DEATH BY 46% AMONG PATIENTS WITH RRMM.BRISTOL-MYERS SQUIBB CO - SAFETY RESULTS FOR EPD WERE CONSISTENT WITH PRIMARY ANALYSIS AND WITH PRIOR FINDINGS FOR EMPLICITI AND POMALIDOMIDE REGIMENS.BRISTOL-MYERS SQUIBB - PATIENTS TREATED WITH EPD CONTINUED TO EXPERIENCE SUSTAINED & CLINICALLY RELEVANT OS AND PFS BENEFITS VERSUS PATIENTS TREATED WITH PD.